PH Seeberger - Chemical Reviews, 2021 - ACS Publications
The glycocalyx, a thick layer of carbohydrates, surrounds the cell wall of most bacterial and parasitic pathogens. Recognition of these unique glycans by the human immune system …
IA Khalil, C Troeger, BF Blacker, PC Rao… - The Lancet infectious …, 2018 - thelancet.com
Summary Background Shigella and enterotoxigenic Escherichia coli (ETEC) are bacterial pathogens that are frequently associated with diarrhoeal disease, and are a significant …
J Liu, JA Platts-Mills, J Juma, F Kabir, J Nkeze, C Okoi… - The Lancet, 2016 - thelancet.com
Background Diarrhoea is the second leading cause of mortality in children worldwide, but establishing the cause can be complicated by diverse diagnostic approaches and varying …
Shigella is the leading cause of global diarrheal deaths that currently lacks a licensed vaccine. Shigellosis drives antimicrobial resistance and leads to economic impact through …
S Baker - Current opinion in infectious diseases, 2018 - journals.lww.com
We need to apply novel findings towards sustainable approaches for treating and preventing Shigella infections. Vaccines and alternative treatments are under development and may …
S Mani, T Wierzba, RI Walker - Vaccine, 2016 - Elsevier
Shigella are gram-negative bacteria that cause severe diarrhea and dysentery. In 2013, Shigella infections caused an estimated 34,400 deaths in children less than five years old …
Background Shigellosis is an acute, severe bacterial colitis that, in high-income countries, is typically associated with travel to high-risk regions (Africa, Asia, and Latin America). Since …
O Rossi, F Citiulo, C Giannelli, E Cappelletti… - NPJ vaccines, 2023 - nature.com
Shigellosis is a leading cause of diarrheal disease in low-middle-income countries (LMICs). Effective vaccines will help to reduce the disease burden, exacerbated by increasing …
RKM Choy, AL Bourgeois… - Clinical Microbiology …, 2022 - Am Soc Microbiol
The timelines for developing vaccines against infectious diseases are lengthy, and often vaccines that reach the stage of large phase 3 field trials fail to provide the desired level of …